This recommendation was based on an analysis of patients with diffuse large B-cell lymphoma undergoing auto-HCT in which the addition of rituximab to the BEAM conditioning regimen had no impact on transplantation outcomes.
These data, in combination with durable complete responses and overall survival data, suggested that tisagenlecleucel improved health-related quality of life in adult patients with relapsed or refractory diffuse large B-cell lymphoma who respond to treatment.
The FDA granted a priority review to selinexor oral tablets for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, who have received at least 2 prior therapies.
Bristol-Meyers Squibb Company announced that the FDA granted a priority review to its BLA for liso-cel to treat patients with relapsed or refractory large B-cell lymphoma.
Researchers found that targeting BCL-W in Burkitt lymphoma and diffuse large B-cell lymphoma may not offer wide-ranging therapeutic benefit.
The data was presented at the EHA-EBMT 2nd European CAR T-Cell Meeting, which took place on January 30, 2020 in Barcelona, Spain, and showed encouraging signs of a manageable safety profile in adults with relapsed/refractory DLBCL.
The phase I trial is evaluating cobomarsen in cancers where the disease process appears to be correlated with an increase in miR-155 levels, including adult T-cell leukemia/lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.
This research could potentially pave the way for possible immunotherapy approaches for common forms of non-Hodgkin lymphoma.
The associate professor at The Ohio State University Comprehensive Cancer Center explained the goals for the future of the CAR T-cell therapy data in patients with DLBCL.
The medical oncologist from the John Theurer Cancer Center noted the importance of real-world data in determining potentially different toxicity profiles in these BTK-inhibitors.